Insider Trading activities at Heron Therapeutics, Inc. /de/ (HRTX)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Heron Therapeutics, Inc. /de/ (HRTX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Heron Therapeutics, Inc. /de/. Table 2 shows the detailed insider transactions. This company's CIK number is 818033.

Total stock buying since 2015: $52,806,683.
Total stock sales since 2015: $125,480,235.
Total stock option exercises since 2015: $22,397,358.

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at *Heron Therapeutics, Inc. /de/* (*HRTX*).
	Insider Buying		Insider Sales		Option Exercises
Year	Shares	Value	Shares	Value	Shares	Value
2025	1,766,546	$2,649,819	0	$0	268,492	$0
2024	0	$0	0	$0	153,978	$0
2023	2,796,744	$3,694,654	0	$0	164,196	$0
2022	0	$0	1,504	$7,153	119,084	$0
2021	0	$0	7,827	$137,664	30,541	$0
2020	0	$0	11,158	$216,176	10,000	$130,000
2019	299,828	$5,247,900	25,109	$644,917	24,000	$312,000
2018	192,308	$5,000,008	3,238,078	$114,912,447	562,259	$4,601,751
2017	2,469,016	$30,121,995	64,626	$990,780	64,626	$576,786
2016	0	$0	300,000	$7,092,451	4,059,202	$15,728,288
2015	271,212	$6,092,307	93,208	$1,478,647	120,929	$1,048,533

Table 2. Monthly summary of insider trading at *Heron Therapeutics, Inc. /de/* (*HRTX*).
Trading Period	Insider Buying		Insider Sales		Option Exercises
year-month	Shares	Value	Shares	Value	Shares	Value
2025-08	1,766,546	$2,649,819	0	$0	0	$0
2025-07	0	$0	0	$0	79,724	$0
2025-06	0	$0	0	$0	25,000	$0
2025-04	0	$0	0	$0	142,223	$0
2025-01	0	$0	0	$0	21,545	$0
2024-10	0	$0	0	$0	21,545	$0
2024-07	0	$0	0	$0	21,547	$0
2024-06	0	$0	0	$0	25,000	$0
2024-04	0	$0	0	$0	84,045	$0
2024-01	0	$0	0	$0	1,841	$0
2023-11	310,000	$287,815	0	$0	0	$0
2023-10	0	$0	0	$0	2,484	$0
2023-07	2,486,744	$3,406,839	0	$0	50,930	$0
2023-04	0	$0	0	$0	19,926	$0
2023-01	0	$0	0	$0	90,856	$0
2022-07	0	$0	0	$0	39,695	$0
2022-05	0	$0	1,504	$7,153	0	$0
2022-04	0	$0	0	$0	39,694	$0
2022-01	0	$0	0	$0	39,695	$0
2021-12	0	$0	550	$5,352	0	$0
2021-10	0	$0	0	$0	7,948	$0
2021-09	0	$0	550	$6,766	0	$0
2021-07	0	$0	0	$0	7,947	$0
2021-06	0	$0	250	$3,800	0	$0

Table 3. Detailed insider trading at *Heron Therapeutics, Inc. /de/* (*HRTX*)
Trade Date	Insider Name	Trade Type	Shares	Price ($)	Value ($)
2025-08-08	Morgan Adam	Buy	1,766,546	1.50	2,649,819
2025-07-31	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	11,695	.00	0
2025-07-31	Collard Craig A (Chief Executive Officer)	Option Ex	34,789	.00	0
2025-07-31	Forbes William P (EVP, Chief Development Officer)	Option Ex	11,695	.00	0
2025-07-19	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	3,874	.00	0
2025-07-19	Collard Craig A (Chief Executive Officer)	Option Ex	13,797	.00	0
2025-07-19	Forbes William P (EVP, Chief Development Officer)	Option Ex	3,874	.00	0
2025-06-16	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	12,500	.00	0
2025-06-06	Forbes William P (EVP, Chief Development Officer)	Option Ex	12,500	.00	0
2025-04-30	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	11,694	.00	0
2025-04-30	Collard Craig A (Chief Executive Officer)	Option Ex	34,789	.00	0
2025-04-30	Forbes William P (EVP, Chief Development Officer)	Option Ex	11,694	.00	0
2025-04-19	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	3,875	.00	0
2025-04-19	Collard Craig A (Chief Executive Officer)	Option Ex	13,796	.00	0
2025-04-19	Forbes William P (EVP, Chief Development Officer)	Option Ex	3,875	.00	0
2025-04-03	Collard Craig A (Chief Executive Officer)	Option Ex	62,500	.00	0
2025-01-19	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	3,874	.00	0
2025-01-19	Collard Craig A (Chief Executive Officer)	Option Ex	13,797	.00	0
2025-01-19	Forbes William P (EVP, Chief Development Officer)	Option Ex	3,874	.00	0
2024-10-19	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	3,874	.00	0
2024-10-19	Collard Craig A (Chief Executive Officer)	Option Ex	13,797	.00	0
2024-10-19	Forbes William P (EVP, Chief Development Officer)	Option Ex	3,874	.00	0
2024-07-19	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	3,875	.00	0
2024-07-19	Collard Craig A (Chief Executive Officer)	Option Ex	13,797	.00	0
2024-07-19	Forbes William P (EVP, Chief Development Officer)	Option Ex	3,875	.00	0
2024-06-16	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	12,500	.00	0
2024-06-06	Forbes William P (EVP, Chief Development Officer)	Option Ex	12,500	.00	0
2024-04-19	Duarte Ira (EVP, Chief Financial Officer)	Option Ex	3,874	.00	0
2024-04-19	Collard Craig A (Chief Executive Officer)	Option Ex	13,797	.00	0
2024-04-19	Forbes William P (EVP, Chief Development Officer)	Option Ex	3,874	.00	0
2024-04-03	Collard Craig A (Chief Executive Officer)	Option Ex	62,500	.00	0
2024-01-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	1,841	.00	0
2023-11-17	Forbes William P (EVP, Chief Development Officer)	Buy	25,000	1.09	27,250
2023-11-16	Duarte Ira (EVP, Chief Financial Officer)	Buy	85,000	.89	75,565
2023-11-16	Collard Craig A (Chief Executive Officer)	Buy	150,000	.92	138,000
2023-11-16	Forbes William P (EVP, Chief Development Officer)	Buy	50,000	.94	47,000
2023-10-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,484	.00	0
2023-07-25	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	42,631	.00	0
2023-07-21	Morgan Adam	Buy	2,486,744	1.37	3,406,839
2023-07-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,485	.00	0
2023-07-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	5,814	.00	0
2023-04-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,484	.00	0
2023-04-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	5,814	.00	0
2023-04-13	Poyhonen John (President & CCO)	Option Ex	5,814	.00	0
2023-04-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	5,814	.00	0
2023-01-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,485	.00	0
2023-01-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	11,628	.00	0
2023-01-13	Quart Barry D (Chief Executive Officer)	Option Ex	39,534	.00	0
2023-01-13	Poyhonen John (President & CCO)	Option Ex	5,814	.00	0
2023-01-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	5,814	.00	0
2022-07-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,485	.00	0
2022-07-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	5,814	.00	0
2022-07-13	Quart Barry D (Chief Executive Officer)	Option Ex	19,768	.00	0
2022-07-13	Poyhonen John (President & CCO)	Option Ex	5,814	.00	0
2022-07-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	5,814	.00	0
2022-05-03	Manhard Kimberly (EVP, Drug Development)	Sale	1,504	4.76	7,153
2022-04-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,484	.00	0
2022-04-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	5,814	.00	0
2022-04-13	Quart Barry D (Chief Executive Officer)	Option Ex	19,768	.00	0
2022-04-13	Poyhonen John (President & CCO)	Option Ex	5,814	.00	0
2022-04-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	5,814	.00	0
2022-01-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	2,485	.00	0
2022-01-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	5,814	.00	0
2022-01-13	Quart Barry D (Chief Executive Officer)	Option Ex	19,768	.00	0
2022-01-13	Poyhonen John (President & CCO)	Option Ex	5,814	.00	0
2022-01-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	5,814	.00	0
2021-12-21	Christian Waage (Director)	Sale	300	9.73	2,920
2021-12-21	Johnson Craig A (Director)	Sale	250	9.73	2,432
2021-10-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	552	.00	0
2021-10-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	1,250	.00	0
2021-10-13	Quart Barry D (Chief Executive Officer)	Option Ex	3,646	.00	0
2021-10-13	Poyhonen John (President & CCO)	Option Ex	1,250	.00	0
2021-10-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	1,250	.00	0
2021-09-21	Christian Waage (Director)	Sale	300	12.31	3,692
2021-09-21	Johnson Craig A (Director)	Sale	250	12.30	3,074
2021-07-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	552	.00	0
2021-07-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	1,250	.00	0
2021-07-13	Quart Barry D (Chief Executive Officer)	Option Ex	3,645	.00	0
2021-07-13	Poyhonen John (President & CCO)	Option Ex	1,250	.00	0
2021-07-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	1,250	.00	0
2021-06-21	Johnson Craig A (Director)	Sale	250	15.20	3,800
2021-05-03	Manhard Kimberly (EVP, Drug Development)	Sale	1,529	17.66	27,008
2021-04-15	Christian Waage (Director)	Sale	300	17.51	5,253
2021-04-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	552	.00	0
2021-04-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	1,250	.00	0
2021-04-13	Quart Barry D (Chief Executive Officer)	Option Ex	3,646	.00	0
2021-04-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	1,250	.00	0
2021-04-06	Johnson Craig A (Director)	Sale	250	17.22	4,305
2021-01-14	Szekeres David Leslie (EVP, Chief Operating Officer)	Sale	827	18.09	14,960
2021-01-13	Peraza Lisa (VP, Chief Accounting Officer)	Option Ex	552	.00	0
2021-01-13	Szekeres David Leslie (EVP, Chief Operating Officer)	Option Ex	1,250	.00	0
2021-01-13	Quart Barry D (Chief Executive Officer)	Option Ex	3,646	.00	0
2021-01-13	Poyhonen John (President & CCO)	Option Ex	1,250	.00	0
2021-01-13	Manhard Kimberly (EVP, Drug Development)	Option Ex	1,250	.00	0
2021-01-08	Szekeres David Leslie (EVP, Chief Operating Officer)	Sale	3,571	19.66	70,220
2020-12-22	Manhard Kimberly (EVP, Drug Development)	Sale	10,000	20.00	200,000
2020-12-22	Manhard Kimberly (EVP, Drug Development)	Option Ex	10,000	13.00	130,000
2020-05-01	Manhard Kimberly (Executive VP, Drug Development)	Sale	1,158	13.97	16,176
2019-11-29	Manhard Kimberly (Executive VP, Drug Development)	Sale	24,000	26.00	624,000
2019-11-29	Manhard Kimberly (Executive VP, Drug Development)	Option Ex	24,000	13.00	312,000
2019-10-04	Tang Kevin C (Director)	Buy	285,714	17.50	4,999,995
2019-10-03	Quart Barry D (Chief Executive Officer)	Buy	4,571	17.50	79,992
2019-10-03	Poyhonen John (EVP, Chief Commercial Officer)	Buy	5,143	17.50	90,002
2019-05-22	Poyhonen John (Director)	Buy	3,000	17.55	52,650
2019-05-15	Christian Waage (Director)	Buy	1,400	18.04	25,261
2019-05-01	Manhard Kimberly (Executive VP, Drug Development)	Sale	1,109	18.86	20,917
2018-11-02	Manhard Kimberly (Executive VP, Drug Development)	Sale	494	30.62	15,124
2018-10-01	Manhard Kimberly (Executive VP, Drug Development)	Sale	6,000	32.07	192,432
2018-10-01	Manhard Kimberly (Executive VP, Drug Development)	Option Ex	6,000	13.00	78,000
2018-09-14	Quart Barry D (Chief Executive Officer)	Option Ex	19,675	7.20	141,660
2018-09-12	Tang Capital Partners Lp (10% Owner)	Sale	2,695,000	35.75	96,346,250
2018-07-02	Rosen Robert (President)	Sale	95,531	38.44	3,672,402
2018-07-02	Rosen Robert (President)	Option Ex	95,531	7.20	687,823
2018-07-02	Manhard Kimberly (Executive VP, Drug Development)	Sale	6,000	38.18	229,074
2018-07-02	Manhard Kimberly (Executive VP, Drug Development)	Option Ex	6,000	13.00	78,000
2018-07-02	Hoffman Robert (CFO & SVP, Finance)	Sale	30,000	38.47	1,154,190
2018-07-02	Hoffman Robert (CFO & SVP, Finance)	Option Ex	30,000	15.30	459,000
2018-06-29	Rosen Robert (President)	Sale	129,469	40.23	5,208,796
2018-06-29	Rosen Robert (President)	Option Ex	129,469	7.20	932,176
2018-06-21	Quart Barry D (Chief Executive Officer)	Sale	50,000	39.05	1,952,499
2018-06-21	Quart Barry D (Chief Executive Officer)	Option Ex	50,000	9.05	452,500
2018-03-29	Tang Capital Partners Lp (10% Owner)	Buy	192,308	26.00	5,000,008
2018-03-19	Quart Barry D (Chief Executive Officer)	Sale	100,000	29.75	2,975,000
2018-03-19	Quart Barry D (Chief Executive Officer)	Option Ex	100,000	7.20	720,000
2018-03-19	Manhard Kimberly (Executive VP, Drug Development)	Sale	18,000	30.00	540,000
2018-03-19	Manhard Kimberly (Executive VP, Drug Development)	Option Ex	18,000	13.00	234,000
2018-03-14	Quart Barry D (Chief Executive Officer)	Sale	100,000	24.75	2,475,000
2018-03-14	Quart Barry D (Chief Executive Officer)	Option Ex	100,000	7.20	720,000
2018-01-10	Manhard Kimberly (Executive VP, Drug Development)	Sale	7,584	20.00	151,680
2018-01-10	Manhard Kimberly (Executive VP, Drug Development)	Option Ex	7,584	13.00	98,592
2017-04-24	Manhard Kimberly (Executive VP, Drug Development)	Sale	43,084	15.33	660,520
2017-04-24	Manhard Kimberly (Executive VP, Drug Development)	Option Ex	43,084	8.93	384,524
2017-01-19	Poyhonen John (Director)	Buy	10,000	12.20	122,000
2017-01-19	Tang Capital Partners Lp (10% Owner)	Buy	2,459,016	12.20	29,999,995
2016-08-10	Rosen Robert (President & CCO)	Sale	100,000	23.55	2,355,400
2016-08-10	Rosen Robert (President & CCO)	Option Ex	100,000	7.20	720,000
2016-07-19	Quart Barry D (Chief Executive Officer)	Option Ex	4,630	7.20	33,336
2016-06-16	Tang Capital Partners Lp (10% Owner)	Option Ex	2,500,000	3.60	9,000,000
2016-04-21	Rosen Robert (President)	Sale	19,662	22.15	435,434
2016-04-21	Rosen Robert (President)	Option Ex	19,662	7.20	141,566
2016-04-20	Rosen Robert (President)	Sale	4,010	22.19	88,965
2016-04-20	Rosen Robert (President)	Option Ex	4,010	7.20	28,872
2016-04-19	Rosen Robert (President)	Sale	176,328	23.89	4,212,652
2016-04-19	Rosen Robert (President)	Option Ex	176,328	7.20	1,269,561
2016-03-21	Marshall Paul (SVP, Technical Operations)	Option Ex	1,100	9.05	9,955
2016-03-02	Quart Barry D (Chief Executive Officer)	Option Ex	3,472	7.20	24,998
2015-12-29	Marshall Paul (SVP, Technical Operations)	Option Ex	1,100	9.05	9,955
2015-12-28	Quart Barry D (Chief Executive Officer)	Option Ex	2,315	7.20	16,668
2015-10-14	Quart Barry D (Chief Executive Officer)	Option Ex	10,000	7.20	72,000
2015-09-29	Quart Barry D (Chief Executive Officer)	Option Ex	14,306	7.20	103,003
2015-08-18	Quart Barry D (Chief Executive Officer)	Option Ex	10,000	7.20	72,000
2015-06-10	Tang Capital Partners Lp (10% Owner)	Buy	121,212	24.75	2,999,997
2015-06-02	Manhard Kimberly (Director)	Sale	10,500	23.58	247,589
2015-06-02	Manhard Kimberly (Director)	Option Ex	10,500	8.80	92,400
2015-06-02	Tang Capital Partners Lp (10% Owner)	Buy	32,395	23.84	772,296
2015-06-01	Manhard Kimberly (Director)	Sale	2,708	21.17	57,328
2015-06-01	Manhard Kimberly (Director)	Option Ex	2,708	9.05	24,507
2015-06-01	Tang Capital Partners Lp (10% Owner)	Buy	2,380	19.30	45,934
2015-05-29	Tang Capital Partners Lp (10% Owner)	Buy	115,225	19.74	2,274,080
2015-03-05	Marshall Paul (SVP, Technical Operations)	Sale	70,000	14.90	1,043,000
2015-03-05	Marshall Paul (SVP, Technical Operations)	Option Ex	70,000	9.40	658,000
2015-03-02	Quart Barry D (Chief Executive Officer)	Sale	10,000	13.07	130,730

Insider trading activities including stock purchases, stock sales, and option exercises of HRTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Heron Therapeutics, Inc. /de/ (symbol HRTX, CIK number 818033) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month